A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1/2, first-in-human, open-label, dose-escalation and cohort expansion
study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics,
preliminary antitumor activity and immunogenicity of 8MW2311 administered by intravenous (IV)
infusion.